Suggested remit: To appraise the clinical and cost effectiveness of ramucirumab within its marketing authorisation for previously treated advanced hepatocellular carcinoma.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
 
Status Suspended
Process STA 2018
ID number 860

Project Team

Project lead Jenna Dilkes

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
24 September 2019 Suspended, The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
24 September 2019 The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
27 June 2018 - 25 July 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
13 February 2018 In progress, DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance